Original Research

Pharmacists are becoming increasingly involved in cancer care. This raises a vital question: How aware are pharmacy students of the expanding roles and opportunities in oncology pharmacy?
The paradigm of oncology practice has changed significantly in recent years with the rapid emergence and use of oral chemotherapy agents.
Treatment of Clostridium difficile infection presents a unique challenge in patients with cancer. C difficile infections are often related to the use of antibiotics and to hospitalizations, and patients undergoing chemotherapy treatment may be at a particularly high risk for infection.

Autologous stem-cell transplantation (ASCT) extends overall survival for patients with multiple myeloma and is a potentially curative treatment option for patients with non-Hodgkin lymphoma (NHL).

Oral chemotherapy agents (OCAs) continue to play an increasing role in the treatment and management of many oncologic diseases.
The use of closed-system transfer devices (CSTDs) for compounding hazardous medications has become an accepted standard of practice to minimize environmental exposure to these agents.
High doses of chemotherapy in patients who undergo autologous hematopoietic stem-cell transplantation (HSCT) can result in delayed or incomplete engraftment. Granulocyte colony-stimulating factors are used to decrease the time to engraftment; however, the optimal timing of filgrastim initiation following autologous HSCT is unknown.
Treatment of chronic myeloid leukemia (CML) with imatinib and more recent therapeutic agents has brought a drastic change in the course of this malignancy. Some patients never experience disease progression, and, therefore, may expect long-term survival with such treatment.
The use of oral chemotherapy has increased dramatically for many types of cancer. This shift from infusion-based therapy introduces new challenges to ensuring safe prescribing, dispensing, administration, and monitoring.
There have been a multitude of advances in the treatment of metastatic melanoma in the past decade, including approval of newer targeted therapies that often are better tolerated than previously used chemotherapy and immunotherapies.
Page 1 of 4
Results 1 - 10 of 33